English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: To compare the immunologic effectiveness of raltegravir–maraviroc (R+M+)-based regimens with raltegravir-based regimens that do not include maraviroc (R+M−) in treatment-experienced patients in clinical practice. Methods: We conducted a retrospective study of treatment-experienced HIV-infected adults receiving either R+M+- or R+M−-based therapy. Longitudinal CD4 counts were analyzed using a linear mixed model. Results: One hundred and fifty-six patients were included in the analysis, of whom 32 were receiving R+M+ and 124 R+M−. Mean baseline CD4 counts in patients on R+M+ and R+M− were 463.8 and 442.3 cells/mm 3 , respectively ( P = .67). In multivariable mixed models, a baseline viral load ≥50 copies/mL was significantly associated with CD4 change during follow-up ( P &lt; .0001). No difference between R+M+ and R+M− was observed during follow-up ( P = .81). Conclusion: CD4 cell recovery was similar among patients receiving either R+M+- or R+M−-based therapy during a 24-month period of follow-up.

journal of the international association of physicians in aids care

Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)